Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar Gel in IgA Nephropathy
NCT02282930Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- Mar 2015
- Primary completion
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of repository corticotropin injection in IgA nephropathy (IgAN), sponsored by Mayo Clinic. Primary endpoint: Number of Subjects With a Complete or Partial Response to Treatment at 12 months. Started Mar 2015; status: completed.
02
Drugs
repository corticotropin injection
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT02282930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282930.